This anti-Sars-CoV-2 Spike protein S1 nanobody was developed by the team of Alejandro Rojas-Fernandez at the Institute of Medicine from the Universidad Austral de Chile. We acquired the exclusive rights to produce this nanobody and make it available for research and development purposes.
Variations: |
|
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Related Products: | - | ||||||||||||
Clone: | W25 | ||||||||||||
Host: | Alpaca | ||||||||||||
Produced in: | E.coli | ||||||||||||
Application: | IF, IHC | ||||||||||||
Dilution: | N/A | ||||||||||||
Capacity: | N/A | ||||||||||||
Antigen: | - | ||||||||||||
Targets: | SARS-CoV-2 S1 | ||||||||||||
Specificity: | Recognizes the RBD of the SARS-CoV-2 S1 protein. | ||||||||||||
Formulation: | DBCO and biotin conjugated sdAbs (1:1 labeling on the c-term.) are lyophilized from PBS pH 7.4. Unconjugated sdAbs are lyophilized from 10 mM KPi pH 6.0,150 mM NaCl, 1 mM EDTA. Reconsitute with 250 µL pure water (unconjugated sdAbs), or with 250 µL 50% glycerol for storage at -80 °C (DBCO-, Biotin-conjugated sdAbs). Use unconjugated sdAbs immediately after reconstitution. | ||||||||||||
kDa: | - | ||||||||||||
Ext Coef: | - | ||||||||||||
Shipping: | Ambient temperature | ||||||||||||
Storing: | Vials containing lyophilized protein can be stored at 4°C for up to 6 months. Vials containing reconstituted protein should be stored at -20°C or below. | ||||||||||||
Protocols: | - | ||||||||||||
References: | - | ||||||||||||
Notice: | To be used in vitro/ for research only. Non-toxic, non-hazardous, non-infectious. | ||||||||||||
Legal terms: | By purchasing this product you agree to our general terms and conditions. |